RxDoctor Payments Data

Andrew Whiteside, DO

Family Medicine · Bay City, MINPI 1710330634

Payments from drug & device makers

$13,917in general payments, 2019–2025

Across 832 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Pfizer$961
  • AstraZeneca$928
  • Bayer$745
  • plus $7K from 41 others

What the payments were for

  • Food & beverage$13,78199%
  • Education$1361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,917 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$91,931
Medicare patients
218
Services billed
2,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$115,496
OzempicSemaglutide54$81,740
XareltoRivaroxaban51$52,721
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$49,565
OxycontinOxycodone Hcl11$44,641
Soliqua 100-33Insulin Glargine/Lixisenatide64$37,945
MounjaroTirzepatide24$25,591
Tresiba Flextouch U-200Insulin Degludec11$13,628
JardianceEmpagliflozin14$13,115
Atorvastatin Calcium512$6,345
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen246$6,175
ArexvyRsvpref3 Antigen/As01e/Pf18$5,576
ShingrixVaricella-Zoster Ge/As01b/Pf22$4,927
Levothyroxine Sodium385$4,175
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$961$115,496102 claims
Novo NordiskOzempic$1,115$81,74054 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$446$60,06788 claims
Johnson & JohnsonXarelto$325$52,72151 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$115$37,94564 claims
Lilly USA, LLCMounjaro$1,365$25,59124 claims
Boehringer IngelheimJardiance$244$13,11514 claims
AbbVieSynthroid$1,574$3,02324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Bay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →